(Q34225077)

31 July 2017

1 reference

title

Opioid poorly-responsive cancer pain. Part 3. Clinical strategies to improve opioid responsiveness (English)

1 reference

31 July 2017

0 references

Mercadante S

1

1 reference

31 July 2017

Portenoy RK

series ordinal

2

1 reference

31 July 2017

publication date

1 April 2001

1 reference

Journal of Pain and Symptom Management

31 July 2017

published in

1 reference

31 July 2017

volume

21

1 reference

31 July 2017

issue

4

1 reference

31 July 2017

page(s)

338-354

1 reference

The nature of opioid responsiveness and its implications for neuropathic pain: new hypotheses derived from studies of opioid infusions

31 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2801%2900250-0

7 January 2021

The Edmonton staging system for cancer pain: preliminary report.

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2801%2900250-0

7 January 2021

Opioid poorly-responsive cancer pain. Part 1: clinical considerations

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2801%2900250-0

7 January 2021

Opioid poorly-responsive cancer pain. Part 2: basic mechanisms that could shift dose response for analgesia

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2801%2900250-0

7 January 2021

Polarised views on treating neurogenic pain

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2801%2900250-0

7 January 2021

Antidepressant-induced analgesia in chronic non-malignant pain: a meta-analysis of 39 placebo-controlled studies

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2801%2900250-0

7 January 2021

Low dose amitriptyline in the treatment of chronic pain

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2801%2900250-0

7 January 2021

Adjuvant analgesic agents

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2801%2900250-0

7 January 2021

Antidepressants increase bioavailability of morphine in cancer patients

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2801%2900250-0

7 January 2021

A systematic review of antidepressants in neuropathic pain

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2801%2900250-0

7 January 2021

Local anesthetics as adjuvant analgesics

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2801%2900250-0

7 January 2021

Systemic local anesthetics in pain control

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2801%2900250-0

7 January 2021

Both intravenous lidocaine and morphine reduce the pain of postherpetic neuralgia

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2801%2900250-0

7 January 2021

Lidocaine test in neuralgia

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2801%2900250-0

7 January 2021

Subcutaneous lidocaine for treatment of neuropathic cancer pain

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2801%2900250-0

7 January 2021

A randomized double-blind crossover trial of intravenous lidocaine in the treatment of neuropathic cancer pain.

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2801%2900250-0

7 January 2021

Response to intravenous lidocaine infusion predicts subsequent response to oral mexiletine: a prospective study

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2801%2900250-0

7 January 2021

Gabapentin for the Treatment of Postherpetic Neuralgia: A Randomized Controlled Trial

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2801%2900250-0

7 January 2021

Gabapentin for the symptomatic treatment of painful neuropathy in patients with diabetes mellitus: a randomized controlled trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2801%2900250-0

7 January 2021

Gabapentin as an adjuvant to opioid analgesia for neuropathic cancer pain

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2801%2900250-0

7 January 2021

Anticonvulsant drugs for management of pain: a systematic review.

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2801%2900250-0

7 January 2021

The benzodiazepines as adjuvant analgesics

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2801%2900250-0

7 January 2021

Systemic adenosine infusion: a new treatment modality to alleviate neuropathic pain.

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2801%2900250-0

7 January 2021

Adenosine and neuropathic pain

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2801%2900250-0

7 January 2021

Post-herpetic neuralgia and topical capsaicin

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2801%2900250-0

7 January 2021

The post-mastectomy pain syndrome and the effect of topical capsaicin

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2801%2900250-0

7 January 2021

Effect of continuous intrathecal infusion of omega-conopeptides, N-type calcium-channel blockers, on behavior and antinociception in the formalin and hot-plate tests in rats

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2801%2900250-0

7 January 2021

Central analgesic activity of nonsteroidal antiinflammatory drugs in animal and human pain models

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2801%2900250-0

7 January 2021

Continuous subcutaneous infusion of ketorolac in cancer neuropathic pain unresponsive to opioid and adjuvant drugs. A case report.

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2801%2900250-0

7 January 2021

Nociceptive nerve pain and neuropathic pain

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2801%2900250-0

7 January 2021

What is the definition of breakthrough pain?

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2801%2900250-0

7 January 2021

Opioid-sparing effect of diclofenac in cancer pain

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2801%2900250-0

7 January 2021

Malignant bone pain: pathophysiology and treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2801%2900250-0

7 January 2021

Predictive factors in advanced cancer pain treated only by analgesics

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2801%2900250-0

7 January 2021

Effect of oral clodronate on metastatic bone pain: a double-blind, placebo-controlled study

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2801%2900250-0

7 January 2021

https://api.crossref.org/works/10.1016%2FS0885-3924%2801%2900250-0

1 reference

7 January 2021

The effect of supportive pamidronate treatment on aspects of quality of life of patients with advanced breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2801%2900250-0

7 January 2021

Palliative pamidronate treatment in patients with bone metastases from breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2801%2900250-0

7 January 2021

Efficacy of Pamidronate in Reducing Skeletal Events in Patients with Advanced Multiple Myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2801%2900250-0

7 January 2021

Pamidronate for pain control in patients with malignant osteolytic bone disease: a prospective dose-effect study

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2801%2900250-0

7 January 2021

Patient-controlled analgesia with nitrous oxide in cancer pain.

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2801%2900250-0

7 January 2021

Antiemetics: neurotransmitter receptor binding predicts therapeutic actions

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2801%2900250-0

7 January 2021

Organic hallucinosis in patients receiving high doses of opiates for cancer pain

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2801%2900250-0

7 January 2021

Pathophysiology and treatment of opioid-related myoclonus in cancer patients

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2801%2900250-0

7 January 2021

Morphine-3-glucuronide may functionally antagonize morphine-6-glucuronide induced antinociception and ventilatory depression in the rat

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2801%2900250-0

7 January 2021

https://api.crossref.org/works/10.1016%2FS0885-3924%2801%2900250-0

1 reference

7 January 2021

Myoclonic spasms during treatment with high doses of intravenous morphine in renal failure

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2801%2900250-0

7 January 2021

Opiate alkaloids antagonize postsynaptic glycine and GABA responses: correlation with convulsant action.

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2801%2900250-0

7 January 2021

Myoclonus associated with treatment with high doses of morphine: the role of supplemental drugs

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2801%2900250-0

7 January 2021

Seizures associated with high-dose intravenous morphine containing sodium bisulfite preservative

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2801%2900250-0

7 January 2021

Benzodiazepines and pain: effects of midazolam on the activities of nociceptive non-specific dorsal horn neurons in the rat spinal cord.

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2801%2900250-0

7 January 2021

Clonazepam treatment of myoclonic contractions associated with high-dose opioids: case report

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2801%2900250-0

7 January 2021

Strychnine-like multifocal myoclonus and seizures in extremely high-dose opioid administration: treatment strategies

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2801%2900250-0

7 January 2021

Continuous midazolam infusion for the management of morphine-induced myoclonus

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2801%2900250-0

7 January 2021

Dextroamphetamine with Morphine for the Treatment of Postoperative Pain

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2801%2900250-0

7 January 2021

The cognitive effects of the administration of narcotic analgesics in patients with cancer pain.

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2801%2900250-0

7 January 2021

Pain in far-advanced cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2801%2900250-0

7 January 2021

Neuropsychological effects of methylphenidate in patients receiving a continuous infusion of narcotics for cancer pain

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2801%2900250-0

7 January 2021

The use of methylphenidate in patients with incident cancer pain receiving regular opiates. A preliminary report

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2801%2900250-0

7 January 2021

Contribution of central neuroplasticity to pathological pain: review of clinical and experimental evidence

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2801%2900250-0

7 January 2021

Evidence of a role for N-methyl-D-aspartate (NMDA) receptors in the facilitation of tail withdrawal after spinal transection.

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2801%2900250-0

7 January 2021

Response of chronic neuropathic pain syndromes to ketamine: a preliminary study.

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2801%2900250-0

7 January 2021

Ketamine as an adjunct to morphine in the treatment of pain

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2801%2900250-0

7 January 2021

Beneficial effects of ketamine in a chronic pain state with allodynia, possibly due to central sensitization.

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2801%2900250-0

7 January 2021

Continuous subcutaneous injection of ketamine for cancer pain.

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2801%2900250-0

7 January 2021

Effective treatment of severe cancer pain of the head using low-dose ketamine in an opioid-tolerant patient

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2801%2900250-0

7 January 2021

Long-term ketamine subcutaneous continuous infusion in neuropathic cancer pain

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2801%2900250-0

7 January 2021

Analgesic effect of intravenous ketamine in cancer patients on morphine therapy: a randomized, controlled, double-blind, crossover, double-dose study

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2801%2900250-0

7 January 2021

Intrathecal ketamine reduces morphine requirements in patients with terminal cancer pain

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2801%2900250-0

7 January 2021

Subpial vacuolar myelopathy after intrathecal ketamine: report of a case

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2801%2900250-0

7 January 2021

Ketobemidone, methadone and pethidine are non-competitive N-methyl-D-aspartate (NMDA) antagonists in the rat cortex and spinal cord

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2801%2900250-0

7 January 2021

Methadone in cancer pain

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2801%2900250-0

7 January 2021

Dextromethorphan. An overview of safety issues

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2801%2900250-0

7 January 2021

Wind-up and the NMDA receptor: from animal studies to humans

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2801%2900250-0

7 January 2021

Oral administration of dextromethorphan prevents the development of morphine tolerance and dependence in rats

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2801%2900250-0

7 January 2021

Magnesium sulphate injected subcutaneously suppresses autotomy in peripherally deafferented rats

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2801%2900250-0

7 January 2021

NMDA receptor blockade in chronic neuropathic pain: a comparison of ketamine and magnesium chloride

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2801%2900250-0

7 January 2021

Enhancement of opiate analgesia by nimodipine in cancer patients chronically treated with morphine: a preliminary report

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2801%2900250-0

7 January 2021

Enhancement of the epidural morphine-induced analgesia by systemic nifedipine

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2801%2900250-0

7 January 2021

Nimodipine fails to enhance the analgesic effect of slow release morphine in the early phases of cancer pain treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2801%2900250-0

7 January 2021

The depressive effect of intrathecal clonidine on the spinal flexor reflex is enhanced after sciatic nerve section in rats

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2801%2900250-0

7 January 2021

The effects of intrathecal morphine and clonidine on the prevention and reversal of spinal cord hyperexcitability following sciatic nerve section in the rat

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2801%2900250-0

7 January 2021

Epidural clonidine analgesia for intractable cancer pain. The Epidural Clonidine Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2801%2900250-0

7 January 2021

Phase I safety assessment of intrathecal neostigmine methylsulfate in humans

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2801%2900250-0

7 January 2021

Analgesic effect of subarachnoid neostigmine in two patients with cancer pain

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2801%2900250-0

7 January 2021

When all else fails: stepwise multiple solutions for a complex cancer pain syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2801%2900250-0

7 January 2021

Small Intrathecal Doses of Lysine-Acetylsalicylate Relieve Intractable Pain in Man

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2801%2900250-0

7 January 2021

Intrathecal injection of lysine acetylsalicylic acid in the rat: a neurotoxicological study

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2801%2900250-0

7 January 2021

Octreotide: a potent new non-opiate analgesic for intrathecal infusion

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2801%2900250-0

7 January 2021

Intrathecal and Epidural Somatostatin for Patients with Cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2801%2900250-0

7 January 2021

Is intrathecal octreotide analgesic or what?

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2801%2900250-0

7 January 2021

Morphine and metabolite behavior after different routes of morphine administration: demonstration of the importance of the active metabolite morphine-6-glucuronide

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2801%2900250-0

7 January 2021

Plasma levels of morphine and morphine glucuronides in the treatment of cancer pain: relationship to renal function and route of administration

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2801%2900250-0

7 January 2021

Morphine-6-glucuronide concentrations and opioid-related side effects: a survey in cancer patients

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2801%2900250-0

7 January 2021

Epidural and subcutaneous morphine in the management of cancer pain: a double-blind cross-over study

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2801%2900250-0

7 January 2021

The use of multiple routes of opioid drug administration in an advanced cancer patient

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2801%2900250-0

7 January 2021

Opioid treatment for radiating cancer pain: oral administration vs. epidural techniques

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2801%2900250-0

7 January 2021

Pain, sedation and reaction time during long-term treatment of cancer patients with oral and epidural opioids

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2801%2900250-0

7 January 2021

Pain characterization in cancer patients and the analgetic response to epidural morphine

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2801%2900250-0

7 January 2021

Analysis of breakthrough pain in 50 patients treated with intrathecal morphine infusion therapy. Development of tolerance or infusion system malfunction

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2801%2900250-0

7 January 2021

Long-term intraspinal infusions of opioids in the treatment of neuropathic pain

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2801%2900250-0

7 January 2021

Long-term intrathecal morphine and bupivacaine in "refractory" cancer pain. I. Results from the first series of 52 patients

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2801%2900250-0

7 January 2021

Long-term intrathecal morphine and bupivacaine in patients with refractory cancer pain. Results from a morphine:bupivacaine dose regimen of 0.5:4.75 mg/ml.

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2801%2900250-0

7 January 2021

Chronic epidural bupivacaine-opioid infusion in intractable cancer pain

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2801%2900250-0

7 January 2021

Epidural versus intrathecal morphine-bupivacaine: assessment of consecutive treatments in advanced cancer pain

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2801%2900250-0

7 January 2021

Intrathecal morphine and bupivacaine in advanced cancer pain patients implanted at home

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2801%2900250-0

7 January 2021

Problems of long-term spinal opioid treatment in advanced cancer patients

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2801%2900250-0

7 January 2021

Intraventricular morphine for intractable pain of advanced cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2801%2900250-0

7 January 2021

Breakthrough pain: definition, prevalence and characteristics

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2801%2900250-0

7 January 2021

Breakthrough pain in cancer patients: pathophysiology and treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2801%2900250-0

7 January 2021

An open label study of oral transmucosal fentanyl citrate (OTFC) for the treatment of breakthrough cancer pain

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2801%2900250-0

7 January 2021

Oral transmucosal fentanyl citrate (OTFC) for the treatment of breakthrough pain in cancer patients: a controlled dose titration study

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2801%2900250-0

7 January 2021

Dose-titration, multicenter study of oral transmucosal fentanyl citrate for the treatment of breakthrough pain in cancer patients using transdermal fentanyl for persistent pain

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2801%2900250-0

7 January 2021

Oral transmucosal fentanyl citrate: randomized, double-blinded, placebo-controlled trial for treatment of breakthrough pain in cancer patients

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2801%2900250-0

7 January 2021

Individual variability in the response to different opioids: report of five cases

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2801%2900250-0

7 January 2021

Clinical efficacy of methadone in patients refractory to other mu-opioid receptor agonist analgesics for management of terminal cancer pain. Case presentations and discussion of incomplete cross-tolerance among opioid agonist analgesics

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2801%2900250-0

7 January 2021

Opioid rotation for toxicity reduction in terminal cancer patients

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2801%2900250-0

7 January 2021

Opioid rotation for cancer pain: rationale and clinical aspects

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2801%2900250-0

7 January 2021

Differential right shifts in the dose-response curve for intrathecal morphine and sufentanil as a function of stimulus intensity

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2801%2900250-0

7 January 2021

The effect of intrinsic efficacy on opioid tolerance

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2801%2900250-0

7 January 2021

Changing pattern of agitated impaired mental status in patients with advanced cancer: Association with cognitive monitoring, hydration, and opioid rotation

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2801%2900250-0

7 January 2021

Disappearance of morphine-induced hyperalgesia after discontinuing or substituting morphine with other opioid agonists

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2801%2900250-0

7 January 2021

Opioid hyperexcitability: the application of alternate opioid therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2801%2900250-0

7 January 2021

Switching from morphine to oral methadone in treating cancer pain: what is the equianalgesic dose ratio?

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2801%2900250-0

7 January 2021

Rapid switching from morphine to methadone in cancer patients with poor response to morphine.

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2801%2900250-0

7 January 2021

Subcutaneous fentanyl and sufentanil infusion substitution for morphine intolerance in cancer pain management

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2801%2900250-0

7 January 2021

Attenuation of morphine-induced delirium in palliative care by substitution with infusion of oxycodone.

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2801%2900250-0

7 January 2021

Radiotherapy for bone pain

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2801%2900250-0

7 January 2021

Radiotherapy for painful bone metastases

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2801%2900250-0

7 January 2021

Role of radiotherapy in metastatic spinal cord compression: preliminary results from a prospective trial

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2801%2900250-0

7 January 2021

Audit of neural blockade for palliative care patients in an acute unit.

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2801%2900250-0

7 January 2021

Interpleural analgesia through a DuPen catheter for lung cancer pain

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2801%2900250-0

7 January 2021

Interpleural analgesia for the treatment of severe cancer pain in terminally ill patients

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2801%2900250-0

7 January 2021

Percutaneous cervical cordotomy and subarachnoid phenol block using fluoroscopy in pain control of costopleural syndrome.

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2801%2900250-0

7 January 2021

Prospective randomized double-blind trial of neurolytic coeliac plexus block in patients with pancreatic cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2801%2900250-0

7 January 2021

Opioid pseudoaddiction--an iatrogenic syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2801%2900250-0

7 January 2021

10.1016/S0885-3924(01)00250-0

Identifiers

DOI

1 reference

31 July 2017

1 reference